FDA submission based on results from Phase III VOYAGER PAD study which showed a significant reduction in the primary efficacy endpoint in patients after lower-extremity revascularization due to symptomatic peripheral artery disease (PAD) / There is currently no Class I Guideline recommended treatment for this patient population / It is estimated that as many as 20 million Americans are living with PAD
Read More